PubMed:31014435 JSONTXT

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":221,"end":224},"obj":"CI"},{"id":"T10","span":{"begin":44,"end":62},"obj":"CI"},{"id":"T11","span":{"begin":247,"end":250},"obj":"CI"},{"id":"T12","span":{"begin":498,"end":501},"obj":"CI"},{"id":"T13","span":{"begin":511,"end":514},"obj":"CI"},{"id":"T14","span":{"begin":525,"end":528},"obj":"CI"},{"id":"T15","span":{"begin":539,"end":542},"obj":"CI"},{"id":"T16","span":{"begin":1156,"end":1159},"obj":"CI"},{"id":"T17","span":{"begin":1976,"end":1979},"obj":"CI"},{"id":"T18","span":{"begin":2141,"end":2144},"obj":"CI"},{"id":"T19","span":{"begin":256,"end":265},"obj":"CI"},{"id":"T2","span":{"begin":494,"end":497},"obj":"CI"},{"id":"T20","span":{"begin":67,"end":76},"obj":"CI"},{"id":"T21","span":{"begin":267,"end":270},"obj":"CI"},{"id":"T22","span":{"begin":502,"end":505},"obj":"CI"},{"id":"T23","span":{"begin":520,"end":523},"obj":"CI"},{"id":"T24","span":{"begin":529,"end":532},"obj":"CI"},{"id":"T25","span":{"begin":547,"end":550},"obj":"CI"},{"id":"T26","span":{"begin":1160,"end":1163},"obj":"CI"},{"id":"T27","span":{"begin":1327,"end":1330},"obj":"CI"},{"id":"T28","span":{"begin":1733,"end":1736},"obj":"CI"},{"id":"T29","span":{"begin":1984,"end":1987},"obj":"CI"},{"id":"T3","span":{"begin":507,"end":510},"obj":"CI"},{"id":"T30","span":{"begin":2193,"end":2196},"obj":"CI"},{"id":"T31","span":{"begin":197,"end":219},"obj":"CI"},{"id":"T32","span":{"begin":20,"end":42},"obj":"CI"},{"id":"T35","span":{"begin":1949,"end":1952},"obj":"DP"},{"id":"T4","span":{"begin":516,"end":519},"obj":"CI"},{"id":"T5","span":{"begin":534,"end":537},"obj":"CI"},{"id":"T6","span":{"begin":1152,"end":1155},"obj":"CI"},{"id":"T7","span":{"begin":1971,"end":1974},"obj":"CI"},{"id":"T8","span":{"begin":2134,"end":2137},"obj":"CI"},{"id":"T9","span":{"begin":227,"end":245},"obj":"CI"},{"id":"T34","span":{"begin":372,"end":375},"obj":"DP"},{"id":"T33","span":{"begin":328,"end":331},"obj":"DP"},{"id":"T36","span":{"begin":306,"end":326},"obj":"DP"},{"id":"T37","span":{"begin":93,"end":113},"obj":"DP"}],"text":"[Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children].\nOBJECTIVE: To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).\nMETHODS: A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.\nRESULTS: After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P\u003c0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P\u003c0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P\u003e0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P\u003e0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P\u003c0.001), while there was no significant difference in this rate among the other groups (P\u003e0.0024).\nCONCLUSIONS: For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":20,"end":42},"obj":"CI"},{"id":"T11","span":{"begin":306,"end":326},"obj":"DP"},{"id":"T12","span":{"begin":328,"end":331},"obj":"DP"},{"id":"T13","span":{"begin":372,"end":375},"obj":"DP"},{"id":"T14","span":{"begin":494,"end":497},"obj":"CI"},{"id":"T15","span":{"begin":498,"end":501},"obj":"CI"},{"id":"T16","span":{"begin":502,"end":505},"obj":"CI"},{"id":"T17","span":{"begin":507,"end":510},"obj":"CI"},{"id":"T18","span":{"begin":511,"end":514},"obj":"CI"},{"id":"T19","span":{"begin":516,"end":519},"obj":"CI"},{"id":"T2","span":{"begin":44,"end":62},"obj":"CI"},{"id":"T20","span":{"begin":520,"end":523},"obj":"CI"},{"id":"T21","span":{"begin":525,"end":528},"obj":"CI"},{"id":"T22","span":{"begin":529,"end":532},"obj":"CI"},{"id":"T23","span":{"begin":534,"end":537},"obj":"CI"},{"id":"T24","span":{"begin":539,"end":542},"obj":"CI"},{"id":"T25","span":{"begin":547,"end":550},"obj":"CI"},{"id":"T26","span":{"begin":1152,"end":1155},"obj":"CI"},{"id":"T27","span":{"begin":1156,"end":1159},"obj":"CI"},{"id":"T28","span":{"begin":1160,"end":1163},"obj":"CI"},{"id":"T29","span":{"begin":1327,"end":1330},"obj":"CI"},{"id":"T3","span":{"begin":67,"end":76},"obj":"CI"},{"id":"T30","span":{"begin":1949,"end":1952},"obj":"DP"},{"id":"T31","span":{"begin":1971,"end":1974},"obj":"CI"},{"id":"T32","span":{"begin":1976,"end":1979},"obj":"CI"},{"id":"T33","span":{"begin":1984,"end":1987},"obj":"CI"},{"id":"T34","span":{"begin":2134,"end":2137},"obj":"CI"},{"id":"T35","span":{"begin":2141,"end":2144},"obj":"CI"},{"id":"T36","span":{"begin":2193,"end":2196},"obj":"CI"},{"id":"T4","span":{"begin":93,"end":113},"obj":"DP"},{"id":"T5","span":{"begin":197,"end":219},"obj":"CI"},{"id":"T6","span":{"begin":221,"end":224},"obj":"CI"},{"id":"T7","span":{"begin":227,"end":245},"obj":"CI"},{"id":"T8","span":{"begin":247,"end":250},"obj":"CI"},{"id":"T9","span":{"begin":256,"end":265},"obj":"CI"},{"id":"T37","span":{"begin":267,"end":270},"obj":"CI"},{"id":"T38","span":{"begin":1733,"end":1736},"obj":"CI"}],"text":"[Clinical effect of fluticasone propionate, montelukast sodium and ketotifen in treatment of cough variant asthma in children].\nOBJECTIVE: To study the clinical effect of different combinations of fluticasone propionate (Flu), montelukast sodium (Mon) and ketotifen (Ket) in the treatment of children with cough variant asthma (CVA).\nMETHODS: A total of 280 children with CVA who were admitted to the department of respiratory medicine from June 2015 to January 2018 were randomly divided into Flu+Mon+Ket, Flu+Mon, Flu+Ket, Mon+Ket, Flu, Mon and Ket groups, with 40 children in each group. The children in each group were given corresponding drug(s), and the course of treatment was 3 months for all groups. The condition of cough, cough symptom score, pulmonary function and adverse drug reactions were evaluated after 2 and 3 months of treatment. The children were followed up to observe recurrence.\nRESULTS: After treatment, cough symptom score tended to decrease in all 7 groups, with increases in percentage of forced expiratory volume in 1 second (FEV1%) and percentage of predicted peak expiratory flow (PEF%). After 2 months of treatment, the Flu+Mon+Ket group had a significantly lower cough symptom score and significantly higher FEV1% and PEF% than the other groups (P\u003c0.05). After 2 and 3 months of treatment, the Ket group had a significantly higher cough symptom score and significantly lower FEV1% and PEF% than the other groups (P\u003c0.05). After 3 months of treatment, there were no significant differences in cough symptom score, FEV1% and PEF% among the other groups (P\u003e0.05). There was a low incidence rate of adverse events in all 7 groups, and there was no significant difference among the 7 groups (P\u003e0.05). The Ket group had a significantly higher recurrence rate of cough than the other groups (P\u003c0.001), while there was no significant difference in this rate among the other groups (P\u003e0.0024).\nCONCLUSIONS: For children with CVA, a combination of Flu, Mon and Ket has a better clinical effect than a combination of two drugs and a single drug at 2 months of treatment and is safe. After 3 months of treatment, Flu or Mon alone has a similar effect to drug combination. Ket alone has a poor clinical effect and a high recurrence rate after drug withdrawal."}